Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Decides to Retire 488,983 Common Shares Valued at Approx. KRW 100B for Price Stabilization and Boosting Shareholder Value

Posted on May 6, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides to Retire 488,983 Common Shares Valued at Approx. KRW 100B for Price Stabilization and Boosting Shareholder Value

Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-05-06

Disclosure Type: Decision on Share Retirement

💡 3-Second Summary

Celltrion has officially announced its decision to retire 488,983 common shares, valued at approximately KRW 100B, aimed at stabilizing the stock price and enhancing shareholder value, with the execution date scheduled for May 21, 2026.

📊 1. [Key Disclosure Details & Major Figures Summary]

  • Purpose of Retirement: Price stabilization and enhancement of shareholder value
  • Type and Number of Shares to be Retired: 488,983 Common Shares (No preferred/other types of shares)
  • Estimated Retirement Value: KRW 100,000,033,000
    • Note: This figure reflects the planned acquisition value approved by the Board of Directors on April 22, 2026, and is subject to amendment if any changes occur.
  • Scheduled Retirement Date: May 21, 2026
  • Acquisition Information for Retirement:
    • Method: On-market acquisition
    • Expected Acquisition Period: April 23, 2026 ~ May 6, 2026 (Based on transaction execution dates)
  • Base Quantity Metric: The volume represents the sum of completed acquisitions and quantities reported to the Korea Exchange as of the board resolution date, which may be adjusted moving forward.
  • Total Outstanding Shares & Par Value: 222,122,341 Common Shares / KRW 1,000 per share
  • Impact on Capital Stock: The process involves retiring treasury shares within the boundaries of dividendable profits. Consequently, only the total number of outstanding common shares will decrease, leaving the company’s registered capital stock completely unchanged.

📈 2. [Expert Perspective: What This Means for Investors]

  • Establishment of the Official Share Retirement Timeline: Linked to the treasury share buyback program previously authorized by the Board on April 22, 2026, this disclosure provides the explicit parameters—stating the share volume, estimated monetary value, and execution date. Market participants can assess this plan based purely on the quantitative specifications disclosed.
  • Physical Reduction of Share Volume with No Impact on Capital: As noted in the official text, the retirement relies on dividendable profits rather than a formal capital write-down. The primary material alteration is that the registered capital stock remains identical, while the absolute number of outstanding shares will be reduced from the current base of 222,122,341 shares.
  • Administrative Notes and Flexible Schedule: The retirement is currently scheduled for May 21, 2026, but the document explicitly mentions that this date might be subject to adjustment during discussions with regulatory authorities. Furthermore, because this operation covers previously acquired treasury shares, this specific filing serves as a substitute for a treasury share disposal disclosure.

📝 Editor’s Comment (by K-STOCK Editor)

This corporate disclosure delivers the fundamental metric that 488,983 common shares will be retired to stabilize prices and improve shareholder metrics. Since the parameters for the share count and estimated value are explicitly labeled as subject to potential subsequent amendments depending on changing variables, investors should look purely at the documented facts rather than speculating on market impacts. The primary milestone to track is simply whether the procedure successfully materializes on the designated date of May 21, 2026.

📢 Disclaimer & Sources

Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) Amends Share Retirement Details, Confirming 488,977 Common Shares for Retirement and Updating Total Value
Next Post: [Disclosure] Celltrion (068270) Reports Q1 2026 Preliminary Consolidated Revenue of KRW 1.14T and Operating Profit of KRW 321.9B, Up 36.00% and 115.41% YoY

Related Posts

[Disclosure] Celltrion (068270) Amends Acquisition Scale of Celltrion USA Shares to KRW 758.8B, Confirming Round 2 Contribution Date on May 13 Disclosures
[Disclosure] Alteogen(196170) Designated as Short Selling Overheated Stock… Short Selling Banned on Jan 22 Disclosures
[Disclosure] Celltrion (068270) Announces Expiration of Part 1 Approval for ‘Remsima SC’ Pediatric Crohn’s Disease Phase 3 Trial in Europe Due to Strategic Shift Disclosures
[Disclosure] SAMSUNG BIOLOGICS(207940) Amends Value of European CMO LOI to KRW 91.4B and Changes Confidentiality Deadline to 2030 Disclosures
[Disclosure] SAMSUNG BIOLOGICS(207940) Reports Full-Year 2024 Consolidated Revenue of KRW 4.55T and Operating Profit of KRW 1.32T Driven by Plant 4 Ramp-up Disclosures
[Disclosure] Celltrion’s (068270) U.S. Subsidiary Signs Large-scale KRW 678.7B CMO Contract with Eli Lilly Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme